Table 4. Correlation between clinicopathological characteristics and ALI in propensity-score matched cohort.
| Characteristics | Overall (N=586) | Low ALI (N=156) | High ALI (N=430) | P value |
|---|---|---|---|---|
| Age (years), n (%) | 0.626 | |||
| ≤60 | 252 (43.00) | 64 (41.03) | 188 (43.72) | |
| >60 | 334 (57.00) | 92 (58.97) | 242 (56.28) | |
| Sex, n (%) | 0.886 | |||
| Female | 166 (28.33) | 43 (27.56) | 123 (28.60) | |
| Male | 420 (71.67) | 113 (72.44) | 307 (71.40) | |
| T stage, n (%) | 0.661 | |||
| T1/2 | 160 (27.30) | 40 (25.64) | 120 (27.91) | |
| T3/4 | 426 (72.70) | 116 (74.36) | 310 (72.09) | |
| Lymph node metastasis, n (%) | 1.000 | |||
| Absence | 202 (34.47) | 54 (34.62) | 148 (34.42) | |
| Presence | 384 (65.53) | 102 (65.38) | 282 (65.58) | |
| TNM stage, n (%) | 0.845 | |||
| I | 127 (21.67) | 32 (20.51) | 95 (22.09) | |
| II | 181 (30.89) | 47 (30.13) | 134 (31.16) | |
| III | 278 (47.44) | 77 (49.36) | 201 (46.74) | |
| Histological type, n (%) | 0.894 | |||
| Differentiated adenocarcinoma | 492 (83.96) | 132 (84.62) | 360 (83.72) | |
| Signet ring cell or mucinous adenocarcinoma | 94 (16.04) | 24 (15.38) | 70 (16.28) | |
| Histological grade, n (%) | 0.398 | |||
| Well/moderately differentiated | 145 (24.74) | 43 (27.56) | 102 (23.72) | |
| Poorly differentiated | 441 (75.26) | 113 (72.44) | 328 (76.28) | |
| Vessel invasion, n (%) | 0.610 | |||
| Absence | 350 (59.73) | 90 (57.69) | 260 (60.47) | |
| Presence | 236 (40.27) | 66 (42.31) | 170 (39.53) | |
| Perineural invasion, n (%) | 0.809 | |||
| Absence | 311 (53.07) | 81 (51.92) | 230 (53.49) | |
| Presence | 275 (46.93) | 75 (48.08) | 200 (46.51) | <0.001* |
| ALI, mean (SD) | 44.09 (26.10) | 16.33 (6.27) | 54.15 (23.10) | <0.001* |
| NLR, mean (SD) | 3.04 (3.26) | 6.17 (5.04) | 1.90 (0.67) | <0.001* |
| ALB (g/dL), mean (SD) | 4.00 (0.51) | 3.73 (0.65) | 4.08 (0.42) | <0.001* |
| BMI (kg/m2), mean (SD) | 21.81 (3.11) | 20.82 (3.09) | 22.175 (3.04) | |
| Overall survival, n (%) | 0.229 | |||
| Alive | 429 (73.21) | 108 (69.23) | 321 (74.65) | |
| Dead | 157 (26.79) | 48 (30.77) | 109 (25.35) | |
| Cancer-specific survival, n (%) | 0.089 | |||
| Alive | 429 (73.21) | 108 (69.23) | 321 (74.65) | |
| Dead due to cancer | 138 (23.55) | 39 (25.00) | 99 (23.02) | |
| Dead of other cause | 19 (3.24) | 9 (5.77) | 10 (2.33) |
*, P value is statistically significant (P<0.05). ALI, advanced lung cancer inflammation index; NLR, neutrophil-lymphocyte ratio; ALB, albumin; BMI, body mass index.